Further experiments were performed to uncover the underlying mechanism of SMIT1 in DLBCL progression using the AKT agonist SC-79, which allows AKT to be phosphorylated by upstream kinases in the cytoplasm. Here, AKT1 is linked to diffuse large B-cell lymphoma.